OUTREACH2
04 May 2022
OUTREACH2
NCT04710641
Radomised Phase II Study of MTL-CEBPA Plus Sorafenib or Sorafenib Alone (OUTREACH2)
Mina Alpha Limited
Cancer Type | Other |
---|---|
Trial Type | Treatment |
Phase | Phase II |
Age Range | 18 years and older |
Sex | All |
Tumour Stream | Liver |
Cancer Stage | Locally Advanced |
Anticipated Start Date | 2022-01-01 |
Anticipated End Date | 2025-05-01 |
Hospital | The Queen Elizabeth Hospital |
---|---|
Clinical Trial Coordinator | Stella Papacharissiou |
stella.papacharissiou@sa.gov.au | |
Phone | 08 8222 6140 |
Principal Investigator | Dr Vy Broadbridge |
Recruitment Status | Not Yet Recruiting |
Keep up to date with the latest news and breakthroughs